Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 6/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | PTGIR | P43119 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4233438 | 0.94 | ACHE (0.37) | MCHR1ACHEPTGIRSMN1; SMN2NPSR1 | |
| SCHEMBL4745445 | 0.90 | MCHR1 (0.38) | MCHR1PTGIRPKMTAS1R3TAS1R1 | |
| SCHEMBL4228512 | 0.89 | SMN1; SMN2 (0.41) | MCHR1ACHEPTGIRSMN1; SMN2NPSR1 | |
| SCHEMBL4237954 | 0.88 | SMN1; SMN2 (0.39) | MCHR1PTGIRSMN1; SMN2NPSR1FGFR1 | |
| SCHEMBL4235345 | 0.86 | PKM (0.38) | MCHR1SMN1; SMN2FGFR1PKMTAS1R3 | |
| SCHEMBL4226836 | 0.86 | SMN1; SMN2 (0.41) | MCHR1ACHEPTGIRSMN1; SMN2NPSR1 | |
| SCHEMBL4234325 | 0.85 | ACHE (0.41) | MCHR1ACHEPTGIRFGFR1KMT2A | |
| SCHEMBL13699242 | 0.85 | PKM (0.37) | MCHR1SMN1; SMN2FGFR1PKMTAS1R3 | |
| SCHEMBL13699144 | 0.84 | SMN1; SMN2 (0.43) | MCHR1ACHEPTGIRSMN1; SMN2NPSR1 | |
| SCHEMBL4236543 | 0.84 | SMN1; SMN2 (0.40) | MCHR1ACHEPTGIRSMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | MCHR1 47/4885ACHE 560/4885PTGIR 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.